DW 1029M

Drug Profile

DW 1029M

Alternative Names: DW-1029M

Latest Information Update: 16 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dong Wha Pharmaceutical
  • Class Herbal medicines
  • Mechanism of Action Advanced glycosylation end product inhibitors; Transforming growth factor beta type I receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic nephropathies

Most Recent Events

  • 16 Dec 2015 Phase II development for Diabetic nephropathies is ongoing in South Korea
  • 09 Aug 2015 Phase II development for Diabetic nephropathies is ongoing in South Korea
  • 01 Feb 2015 Dong Wha Pharmaceutical completes a phase I drug-interaction trial in Healthy volunteers in South Korea (NCT02212769)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top